The Filing Desk

Glass House Brands vs Stoke Therapeutics

Glass House Brands GLAS · Stoke Therapeutics STOK · Pharmaceuticals

Stoke Therapeutics reported revenue of $184 million in fiscal 2025, about the same as Glass House Brands' $182 million in fiscal 2025. Glass House Brands' revenue fell 9.4% in its latest year, and Stoke Therapeutics' grew 404.5%. Glass House Brands had an operating margin of -9.1%, against -11.2% at Stoke Therapeutics. Free cash flow was −$16 million at Glass House Brands and $45 million at Stoke Therapeutics.

Side by side

Glass House BrandsStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$182M$184M
Revenue growth−9.4%404.5%
Revenue growth a year, last 5 years30.4%—
Gross margin42.3%—
Operating margin−9.1%−11.2%
Net margin−16.3%−3.7%
Free cash flow−$16M$45M
Free cash flow margin−8.6%24.4%
Return on capital−10.0%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count8.9%9.7%
Last close$1.21$26.93
P/E at the last close——
Insider trades, last 12 monthssold $353,762sold $7.6 million
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Glass House BrandsStoke Therapeutics
Operating margin
Percent of revenue
Glass House BrandsStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Glass House BrandsStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Glass House Brands and Stoke Therapeutics pages.